MarketPulse

Ryoncil®

6 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Mesoblast Limited

Mesoblast Hits $30.3M Ryoncil Revenue as Cash Burn Slows to $4.1M

Mesoblast reports Q3 FY2026 Ryoncil revenues of $30.3M, approaching $100M cumulative sales, while reducing operating cash spend and strengthening balance sheet.
MESOFDA approvalrevenue growth
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Mesoblast Wins FDA Green Light for Direct Path to DMD Approval Trial

Mesoblast receives IND clearance to proceed directly to registrational trial for Ryoncil in Duchenne muscular dystrophy, potentially accelerating path to market approval.
MESORyoncil®cell therapy
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Mesoblast's Ryoncil Hits $30.3M in Q1 as First-Year Sales Near $100M Milestone

Mesoblast reports $30.3M quarterly sales for Ryoncil, its FDA-approved cell therapy for pediatric graft-versus-host disease, approaching $100M in first-year revenue.
MESOFDA approvalRyoncil®
GlobeNewswire Inc.GlobeNewswire Inc.··Mesoblast Limited

Mesoblast Plans First R&D Day to Showcase Pipeline, New Cell Therapy Tech

Mesoblast Limited will host inaugural R&D Day April 8, 2026 in NYC, featuring Ryoncil commercialization updates and new cellular medicine technology.
MESORyoncil®cellular medicines
GlobeNewswire Inc.GlobeNewswire Inc.··Mesoblast Limited

Mesoblast Taps Regeneron Veteran as Clinical Chief to Expand Cell Therapy Pipeline

Mesoblast appoints veteran biotech executive Dr. Teresa Montagut as Head of Clinical Development, signaling acceleration in cell therapy pipeline expansion and Ryoncil® indication broadening.
MESOclinical developmentRyoncil®
GlobeNewswire Inc.GlobeNewswire Inc.··Mesoblast Limited

Mesoblast Posts Strong H1 Results on Ryoncil® Commercial Traction

Mesoblast reports strong H1 results with Ryoncil® revenue of $51.3M and narrowed net losses. Commercial expansion underway with 49 transplant centers operational and FY2026 guidance of $110-120M revenue.
MESOfinancial resultsFDA approval